Business Context and Reporting Period
This Form 8-K Current Report was filed by Alector, Inc. on December 15, 2021. The filing primarily addresses Item 5.02 regarding the appointment of a new senior executive officer.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figures disclosed relate to the compensation package for the newly appointed executive:
- Base Salary: $570,000 annually.
- Target Bonus: 100% of base salary ($570,000).
- Sign-on Bonus: $500,000.
- Equity Awards: 300,000 stock options (4-year vest), 59,000 restricted stock units (3-year vest), and 59,000 performance share units (1-year vest).
Material Changes
The material change reported is the appointment of Saraswati (Sara) Kenkare-Mitra, Ph.D., as President and Head of Research and Development, effective December 15, 2021. Dr. Kenkare-Mitra joins Alector after a 23-year tenure at Genentech, where she most recently served as Senior Vice President of Development Sciences.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, financial outlook, or discussion of general business risks. It notes that Dr. Kenkare-Mitra has entered into standard Indemnification and Change in Control/Severance agreements (Tier 2 level). The filing explicitly states that the accompanying press release is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
Investor Verification Checklist
- Verify the terms of the Offer Letter (Exhibit 99.1) for specific performance thresholds attached to the performance share units.
- Review the standard Change in Control and Severance Agreement referenced from the 2019 Form S-1 to understand potential termination costs.
- Confirm the impact of the new executive leadership on the company's drug development pipeline, as no specific project updates are included in this filing.